Silence Therapeutics plc (LON:SLN – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 535 ($6.72) and traded as low as GBX 512 ($6.43). Silence Therapeutics shares last traded at GBX 535 ($6.72), with a volume of 913,528 shares traded.
Silence Therapeutics Stock Down 0.9 %
The firm has a market capitalization of £480.35 million and a PE ratio of -11.01. The firm’s 50-day moving average is GBX 535 and its 200 day moving average is GBX 535. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.36 and a current ratio of 4.52.
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.
See Also
- Five stocks we like better than Silence Therapeutics
- What Are the FAANG Stocks and Are They Good Investments?
- The 3 Hottest Insiders Buys This Month
- Conference Calls and Individual Investors
- What Bulls and Bears May Be Getting Wrong about SOFI Stock
- Airline Stocks – Top Airline Stocks to Buy Now
- Microsoft Analysis: Trends, Predictions & Investment Insight
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
